← Back to Screener
Definium Therapeutics, Inc. Common Shares (DFTX)
Price$23.55
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)78.24%
Price vs S&P 500 (4W)6.81%
VGM Score85.04
Market Capitalization$2.57B
All Metrics
Book Value / Share (Quarterly)$2.68
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.39
Price vs S&P 500 (YTD)67.72%
EPS (TTM)$-2.49
10-Day Avg Trading Volume2.29M
EPS Excl Extra (TTM)$-2.49
EPS (Annual)$-2.06
ROI (Annual)-49.29%
Cash / Share (Quarterly)$3.59
ROA (Last FY)-41.76%
EBITD / Share (TTM)$-2.03
ROE (5Y Avg)-64.36%
Cash Flow / Share (Annual)$-1.33
P/B Ratio9.21x
P/B Ratio (Quarterly)6.76x
Net Income / Employee (Annual)$-1,750,400
Net Interest Coverage (TTM)-208.31x
ROA (TTM)-70.73%
EPS Incl Extra (Annual)$-2.06
Current Ratio (Annual)6.29x
Quick Ratio (Quarterly)4.60x
3-Month Avg Trading Volume1.76M
52-Week Price Return206.24%
Revenue / Employee (TTM)$0
52-Week High$26.25
EPS Excl Extra (Annual)$-2.06
26-Week Price Return86.17%
Quick Ratio (Annual)6.17x
13-Week Price Return34.19%
Total Debt / Equity (Annual)0.12x
Current Ratio (Quarterly)4.69x
Enterprise Value$2.35B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.17
3-Month Return Std Dev54.03%
Net Income / Employee (TTM)$-2,262,300
ROE (Last FY)-55.30%
Net Interest Coverage (Annual)-192.15x
EPS Basic Excl Extra (Annual)$-2.06
Total Debt / Equity (Quarterly)0.15x
EPS Incl Extra (TTM)$-2.49
ROI (TTM)-87.16%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)181.88%
Year-to-Date Return75.88%
5-Day Price Return-2.12%
EPS Normalized (Annual)$-2.06
ROA (5Y Avg)-48.95%
Month-to-Date Return-2.65%
EBITD / Share (Annual)$-1.86
LT Debt / Equity (Annual)0.12x
ROI (5Y Avg)-58.66%
LT Debt / Equity (Quarterly)0.15x
EPS Basic Excl Extra (TTM)$-2.49
P/B Ratio (Annual)4.04x
Book Value / Share (Annual)$3.36
Price vs S&P 500 (13W)25.93%
Beta2.44x
Revenue / Share (TTM)$0.00
ROE (TTM)-102.48%
52-Week Low$6.34
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-0.71est. -0.50
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.29
4.30
4.32
Industry Peers — Pharmaceutical Preparations(17)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DFTXDefinium Therapeutics, Inc. Common Shares | — | — | A | $23.55 |
| CRONCronos Group Inc. Common Share | C | B | B | $2.74 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | $4.94 |
| CGCCanopy Growth Corporation Common Shares | C | D | C | $1.03 |
| USNAUSANA Health Sciences Inc | B | D | C | $18.03 |
| NAGENiagen Bioscience, Inc. Common Stock | C | B | D | $3.45 |
| SNDLSundial Growers Inc. Common Shares | A | C | C | $1.42 |
| ACBAurora Cannabis Inc. Common Shares | B | C | C | $3.38 |
| MDWDMediWound Ltd. | D | F | D | $14.18 |
| FTLFFitLife Brands, Inc. Common Stock | B | C | D | $9.87 |
| BTMDBiote Corp. Class A Common Stock | B | D | C | $2.34 |
About
Definium Therapeutics develops novel therapeutics targeting the underlying causes of psychiatric and neurological disorders, aiming for long-term patient remission rather than symptom management. Its pipeline includes four Phase 3 trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD), led by DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. The company is advancing commercial and operational readiness ahead of potential product launch.